University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

December 23, 2024

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

December 10, 2024

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

November 08, 2024

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

September 08, 2024

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

September 04, 2024

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

August 22, 2024

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

August 20, 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

August 15, 2024

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

August 12, 2024

Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.

July 05, 2024

Chih-Yi Liao, MD, discusses treatment considerations for patients with hepatocellular carcinoma and emphasizes the need for a multidisciplinary approach.

July 03, 2024

Chih-Yi Liao, MD, discusses the treatment landscape of advanced biliary tract cancer and outlines therapy selection factors.

June 17, 2024

Dr Rosenberg discusses strategies for managing nasopharyngeal cancer and the role of toripalimab in this treatment paradigm.

May 30, 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

May 22, 2024

Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.

May 14, 2024

May 02, 2024

Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, review cases of patients with colorectal cancer and provide insights on clinical practice.

May 02, 2024

Turning the focus of the conversation to clinical practice, experts on hepatic artery infusion therapy provide clinical insights on program development and evolution.

May 02, 2024

Drs Connell and Merkow discuss the current treatment landscape in intrahepatic cholangiocarcinoma and review recent clinical data in that space.

May 02, 2024

Louise Catherine Connell, MB BCh BAO, BMedSc, and Ryan Merkow, MD, MS, review clinical trial data on resected colorectal cancer liver metastases.

May 02, 2024

A surgical oncologist and gastrointestinal oncologist review data on hepatic artery infusion therapy in unresectable colorectal cancer liver metastases.